| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition | 49 | 2020 | 553 | 9.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 55 | 2020 | 1428 | 8.030 |
Why?
|
| Life Style | 40 | 2020 | 408 | 5.650 |
Why?
|
| Cognition Disorders | 33 | 2020 | 384 | 5.630 |
Why?
|
| Obesity | 50 | 2020 | 1176 | 5.420 |
Why?
|
| Overweight | 22 | 2020 | 279 | 4.510 |
Why?
|
| Weight Loss | 34 | 2020 | 480 | 3.660 |
Why?
|
| Estrogens, Conjugated (USP) | 20 | 2020 | 128 | 3.330 |
Why?
|
| Women's Health | 24 | 2020 | 236 | 3.300 |
Why?
|
| Aged | 149 | 2020 | 10332 | 3.250 |
Why?
|
| Aging | 27 | 2020 | 945 | 3.220 |
Why?
|
| Postmenopause | 31 | 2020 | 414 | 3.060 |
Why?
|
| Dementia | 21 | 2020 | 252 | 2.980 |
Why?
|
| Female | 182 | 2020 | 19916 | 2.740 |
Why?
|
| Estrogen Replacement Therapy | 19 | 2020 | 188 | 2.710 |
Why?
|
| Exercise | 25 | 2020 | 672 | 2.610 |
Why?
|
| Humans | 204 | 2020 | 31976 | 2.310 |
Why?
|
| Brain | 17 | 2020 | 949 | 2.250 |
Why?
|
| Hormone Replacement Therapy | 10 | 2020 | 88 | 1.950 |
Why?
|
| Weight Gain | 17 | 2020 | 117 | 1.880 |
Why?
|
| Medroxyprogesterone Acetate | 13 | 2020 | 93 | 1.880 |
Why?
|
| Aged, 80 and over | 64 | 2020 | 3998 | 1.870 |
Why?
|
| Memory | 9 | 2018 | 190 | 1.820 |
Why?
|
| Geriatric Assessment | 12 | 2018 | 391 | 1.780 |
Why?
|
| Middle Aged | 85 | 2020 | 11845 | 1.760 |
Why?
|
| Cardiovascular Diseases | 24 | 2020 | 1125 | 1.710 |
Why?
|
| Ankle Brachial Index | 4 | 2015 | 39 | 1.560 |
Why?
|
| Male | 97 | 2020 | 19155 | 1.530 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2020 | 507 | 1.490 |
Why?
|
| Risk Factors | 53 | 2020 | 3867 | 1.450 |
Why?
|
| Follow-Up Studies | 32 | 2020 | 2279 | 1.430 |
Why?
|
| Behavior Therapy | 9 | 2020 | 103 | 1.420 |
Why?
|
| Exercise Therapy | 10 | 2020 | 270 | 1.370 |
Why?
|
| Blood Pressure | 12 | 2016 | 845 | 1.350 |
Why?
|
| Research Design | 15 | 2020 | 311 | 1.310 |
Why?
|
| Body Weight | 10 | 2020 | 308 | 1.270 |
Why?
|
| Particulate Matter | 6 | 2020 | 31 | 1.250 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2020 | 1324 | 1.250 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 300 | 1.250 |
Why?
|
| Disability Evaluation | 8 | 2020 | 240 | 1.190 |
Why?
|
| Neuropsychological Tests | 19 | 2019 | 371 | 1.130 |
Why?
|
| Body Mass Index | 18 | 2020 | 922 | 1.090 |
Why?
|
| Memory Disorders | 2 | 2016 | 54 | 1.040 |
Why?
|
| Cohort Studies | 19 | 2020 | 1821 | 1.000 |
Why?
|
| Motor Activity | 7 | 2015 | 325 | 0.990 |
Why?
|
| Time Factors | 17 | 2020 | 2150 | 0.990 |
Why?
|
| Risk Reduction Behavior | 10 | 2020 | 125 | 0.990 |
Why?
|
| Football | 7 | 2020 | 77 | 0.980 |
Why?
|
| Diet Therapy | 4 | 2020 | 15 | 0.980 |
Why?
|
| Incidence | 18 | 2020 | 1200 | 0.940 |
Why?
|
| Estrogens | 8 | 2015 | 167 | 0.940 |
Why?
|
| Sex Characteristics | 4 | 2020 | 171 | 0.900 |
Why?
|
| Patient Selection | 9 | 2016 | 277 | 0.900 |
Why?
|
| Air Pollution | 3 | 2020 | 18 | 0.870 |
Why?
|
| Alzheimer Disease | 8 | 2020 | 327 | 0.840 |
Why?
|
| United States | 29 | 2020 | 3936 | 0.840 |
Why?
|
| Health Behavior | 7 | 2019 | 231 | 0.830 |
Why?
|
| Depression | 10 | 2019 | 443 | 0.820 |
Why?
|
| Health Status Indicators | 4 | 2020 | 73 | 0.810 |
Why?
|
| Hypertension | 13 | 2015 | 956 | 0.800 |
Why?
|
| Tamoxifen | 2 | 2013 | 56 | 0.800 |
Why?
|
| Chronic Disease | 4 | 2020 | 401 | 0.760 |
Why?
|
| Cerebrovascular Circulation | 2 | 2020 | 92 | 0.750 |
Why?
|
| Erythrocytes | 9 | 2020 | 48 | 0.740 |
Why?
|
| Physical Fitness | 6 | 2013 | 131 | 0.740 |
Why?
|
| Brain Ischemia | 5 | 2020 | 145 | 0.730 |
Why?
|
| Cross-Sectional Studies | 17 | 2018 | 1527 | 0.720 |
Why?
|
| Longitudinal Studies | 14 | 2020 | 766 | 0.710 |
Why?
|
| Caloric Restriction | 3 | 2020 | 106 | 0.710 |
Why?
|
| Patient Education as Topic | 9 | 2017 | 271 | 0.700 |
Why?
|
| Fatty Acids, Omega-3 | 5 | 2020 | 56 | 0.670 |
Why?
|
| Problem Solving | 1 | 2018 | 28 | 0.640 |
Why?
|
| Logistic Models | 15 | 2018 | 781 | 0.630 |
Why?
|
| Mobility Limitation | 7 | 2020 | 219 | 0.620 |
Why?
|
| Health Care Costs | 2 | 2020 | 117 | 0.610 |
Why?
|
| Health Education | 9 | 2018 | 157 | 0.610 |
Why?
|
| Treatment Outcome | 19 | 2020 | 3314 | 0.600 |
Why?
|
| Metformin | 2 | 2018 | 22 | 0.590 |
Why?
|
| Environmental Exposure | 6 | 2020 | 91 | 0.570 |
Why?
|
| Single-Blind Method | 9 | 2020 | 203 | 0.560 |
Why?
|
| Caffeine | 1 | 2016 | 29 | 0.560 |
Why?
|
| Decision Making | 1 | 2018 | 194 | 0.550 |
Why?
|
| Activities of Daily Living | 6 | 2011 | 259 | 0.540 |
Why?
|
| Disabled Persons | 4 | 2018 | 105 | 0.530 |
Why?
|
| Health Status | 6 | 2020 | 399 | 0.530 |
Why?
|
| Diet, Reducing | 4 | 2020 | 106 | 0.520 |
Why?
|
| Health Services | 2 | 2020 | 38 | 0.520 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 761 | 0.510 |
Why?
|
| Veterans | 1 | 2015 | 66 | 0.500 |
Why?
|
| Walking | 10 | 2016 | 210 | 0.490 |
Why?
|
| Organ Size | 8 | 2020 | 209 | 0.490 |
Why?
|
| Age Factors | 14 | 2018 | 1191 | 0.490 |
Why?
|
| Alcohol Drinking | 4 | 2019 | 247 | 0.470 |
Why?
|
| Depressive Disorder | 4 | 2018 | 75 | 0.450 |
Why?
|
| Adult | 27 | 2020 | 9340 | 0.450 |
Why?
|
| Refusal to Participate | 1 | 2013 | 4 | 0.440 |
Why?
|
| Prevalence | 8 | 2018 | 981 | 0.440 |
Why?
|
| Risk | 7 | 2017 | 319 | 0.440 |
Why?
|
| Biomedical Research | 3 | 2018 | 155 | 0.440 |
Why?
|
| Antihypertensive Agents | 3 | 2017 | 351 | 0.440 |
Why?
|
| Carotid Artery Diseases | 5 | 2013 | 114 | 0.430 |
Why?
|
| Linear Models | 8 | 2018 | 448 | 0.420 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 58 | 0.420 |
Why?
|
| Pilot Projects | 11 | 2017 | 543 | 0.420 |
Why?
|
| Dietary Supplements | 4 | 2019 | 185 | 0.410 |
Why?
|
| Air Pollutants | 3 | 2020 | 24 | 0.400 |
Why?
|
| Prospective Studies | 15 | 2020 | 2282 | 0.390 |
Why?
|
| Psychomotor Performance | 2 | 2011 | 99 | 0.390 |
Why?
|
| Medication Adherence | 1 | 2013 | 160 | 0.390 |
Why?
|
| Diabetes Complications | 3 | 2018 | 177 | 0.380 |
Why?
|
| Remote Consultation | 1 | 2011 | 12 | 0.380 |
Why?
|
| Physical Exertion | 1 | 2011 | 13 | 0.380 |
Why?
|
| Adolescent | 18 | 2020 | 3515 | 0.370 |
Why?
|
| Urban Population | 1 | 2011 | 89 | 0.370 |
Why?
|
| Head | 3 | 2020 | 51 | 0.360 |
Why?
|
| Principal Component Analysis | 2 | 2012 | 68 | 0.360 |
Why?
|
| Mortality | 3 | 2017 | 125 | 0.360 |
Why?
|
| Eicosapentaenoic Acid | 5 | 2017 | 29 | 0.360 |
Why?
|
| Psychological Tests | 2 | 2010 | 35 | 0.360 |
Why?
|
| Diet | 6 | 2020 | 386 | 0.360 |
Why?
|
| Multicenter Studies as Topic | 4 | 2009 | 105 | 0.350 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2010 | 34 | 0.350 |
Why?
|
| Residence Characteristics | 1 | 2011 | 191 | 0.350 |
Why?
|
| Stroke | 1 | 2015 | 584 | 0.340 |
Why?
|
| Mass Screening | 2 | 2013 | 264 | 0.340 |
Why?
|
| Longevity | 3 | 2020 | 24 | 0.340 |
Why?
|
| Double-Blind Method | 11 | 2019 | 525 | 0.330 |
Why?
|
| Head Injuries, Closed | 2 | 2019 | 16 | 0.330 |
Why?
|
| Brachial Artery | 2 | 2008 | 69 | 0.320 |
Why?
|
| Quality of Life | 5 | 2018 | 933 | 0.320 |
Why?
|
| Docosahexaenoic Acids | 4 | 2017 | 21 | 0.320 |
Why?
|
| Cholesterol, HDL | 6 | 2018 | 177 | 0.320 |
Why?
|
| Proportional Hazards Models | 12 | 2020 | 757 | 0.320 |
Why?
|
| Frail Elderly | 2 | 2009 | 69 | 0.320 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 35 | 0.310 |
Why?
|
| Brain Concussion | 3 | 2020 | 62 | 0.310 |
Why?
|
| Adipose Tissue | 3 | 2013 | 347 | 0.310 |
Why?
|
| Risk Assessment | 7 | 2018 | 1434 | 0.310 |
Why?
|
| Affect | 3 | 2018 | 69 | 0.300 |
Why?
|
| Comorbidity | 6 | 2017 | 567 | 0.300 |
Why?
|
| Mental Status Schedule | 3 | 2017 | 24 | 0.300 |
Why?
|
| Young Adult | 13 | 2020 | 2607 | 0.290 |
Why?
|
| Athletic Injuries | 2 | 2019 | 82 | 0.290 |
Why?
|
| Health Promotion | 5 | 2015 | 246 | 0.290 |
Why?
|
| Feeding Behavior | 4 | 2019 | 161 | 0.290 |
Why?
|
| Vitamin E | 1 | 2006 | 23 | 0.280 |
Why?
|
| Sulfonylurea Compounds | 2 | 2018 | 7 | 0.280 |
Why?
|
| Geriatrics | 1 | 2008 | 85 | 0.280 |
Why?
|
| Disease Progression | 6 | 2017 | 591 | 0.280 |
Why?
|
| Eating | 2 | 2018 | 74 | 0.280 |
Why?
|
| Fatty Acids, Unsaturated | 3 | 2017 | 35 | 0.270 |
Why?
|
| Antioxidants | 1 | 2006 | 114 | 0.270 |
Why?
|
| Craniocerebral Trauma | 2 | 2017 | 56 | 0.260 |
Why?
|
| Tunica Intima | 3 | 2005 | 57 | 0.260 |
Why?
|
| Head Protective Devices | 4 | 2018 | 48 | 0.250 |
Why?
|
| Executive Function | 2 | 2015 | 57 | 0.250 |
Why?
|
| Independent Living | 3 | 2019 | 99 | 0.250 |
Why?
|
| Internet | 2 | 2013 | 195 | 0.240 |
Why?
|
| Acceleration | 3 | 2020 | 65 | 0.240 |
Why?
|
| Telemetry | 3 | 2020 | 26 | 0.240 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 765 | 0.240 |
Why?
|
| Blood Glucose | 6 | 2015 | 492 | 0.230 |
Why?
|
| Artificial Intelligence | 3 | 2013 | 51 | 0.230 |
Why?
|
| Telephone | 3 | 2016 | 59 | 0.230 |
Why?
|
| Carotid Artery, Common | 1 | 2003 | 39 | 0.230 |
Why?
|
| Waist Circumference | 3 | 2020 | 90 | 0.230 |
Why?
|
| Decision Support Techniques | 1 | 2005 | 128 | 0.230 |
Why?
|
| Exercise Test | 4 | 2013 | 227 | 0.220 |
Why?
|
| Social Support | 2 | 2017 | 179 | 0.220 |
Why?
|
| Calcium Carbonate | 2 | 2013 | 8 | 0.220 |
Why?
|
| Menopause | 3 | 2020 | 92 | 0.220 |
Why?
|
| Cholecalciferol | 2 | 2013 | 20 | 0.220 |
Why?
|
| Analysis of Variance | 3 | 2014 | 462 | 0.220 |
Why?
|
| Potassium | 1 | 2002 | 39 | 0.210 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2002 | 28 | 0.210 |
Why?
|
| Fatty Acids | 2 | 2014 | 97 | 0.210 |
Why?
|
| Endothelium, Vascular | 2 | 2019 | 156 | 0.210 |
Why?
|
| Patient Compliance | 2 | 2015 | 224 | 0.210 |
Why?
|
| Medroxyprogesterone | 2 | 2017 | 14 | 0.210 |
Why?
|
| Adiposity | 2 | 2020 | 199 | 0.210 |
Why?
|
| Athletes | 3 | 2018 | 69 | 0.200 |
Why?
|
| Cause of Death | 5 | 2018 | 238 | 0.200 |
Why?
|
| Antidepressive Agents | 2 | 2013 | 74 | 0.200 |
Why?
|
| Autoimmune Diseases | 3 | 2009 | 49 | 0.200 |
Why?
|
| Socioeconomic Factors | 3 | 2013 | 420 | 0.200 |
Why?
|
| Sex Factors | 5 | 2016 | 663 | 0.200 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2011 | 44 | 0.190 |
Why?
|
| Models, Biological | 2 | 2016 | 391 | 0.190 |
Why?
|
| Maternal Mortality | 3 | 2007 | 12 | 0.190 |
Why?
|
| Waist-Hip Ratio | 2 | 2011 | 34 | 0.190 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 273 | 0.180 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3523 | 0.180 |
Why?
|
| Health Surveys | 3 | 2016 | 197 | 0.180 |
Why?
|
| Genotype | 2 | 2020 | 733 | 0.180 |
Why?
|
| Vision Disorders | 1 | 2020 | 23 | 0.180 |
Why?
|
| Hysterectomy | 2 | 2011 | 45 | 0.180 |
Why?
|
| Urinary Incontinence | 2 | 2012 | 47 | 0.180 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 14 | 0.180 |
Why?
|
| Athletic Performance | 1 | 2020 | 12 | 0.180 |
Why?
|
| Estradiol | 2 | 2013 | 128 | 0.180 |
Why?
|
| Insulin Resistance | 3 | 2013 | 461 | 0.180 |
Why?
|
| Hearing Loss | 1 | 2020 | 26 | 0.170 |
Why?
|
| Apolipoprotein E4 | 1 | 2020 | 63 | 0.170 |
Why?
|
| Computer Simulation | 1 | 2021 | 221 | 0.170 |
Why?
|
| Visual Acuity | 1 | 2020 | 73 | 0.170 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 181 | 0.170 |
Why?
|
| Models, Animal | 2 | 2020 | 164 | 0.170 |
Why?
|
| Seasons | 2 | 2018 | 87 | 0.170 |
Why?
|
| Cacao | 1 | 2019 | 4 | 0.170 |
Why?
|
| Population Surveillance | 1 | 2020 | 125 | 0.170 |
Why?
|
| Optic Nerve | 1 | 2019 | 17 | 0.170 |
Why?
|
| Mouth Protectors | 1 | 2019 | 5 | 0.170 |
Why?
|
| European Continental Ancestry Group | 6 | 2013 | 1167 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2018 | 354 | 0.170 |
Why?
|
| Optic Nerve Diseases | 1 | 2019 | 19 | 0.170 |
Why?
|
| Soccer | 1 | 2019 | 19 | 0.170 |
Why?
|
| Medicare | 1 | 2020 | 207 | 0.170 |
Why?
|
| Glucose Tolerance Test | 2 | 2013 | 125 | 0.160 |
Why?
|
| Inflammation | 3 | 2018 | 530 | 0.160 |
Why?
|
| Vitamins | 1 | 2019 | 68 | 0.160 |
Why?
|
| Plant Extracts | 1 | 2019 | 61 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 834 | 0.160 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2018 | 11 | 0.160 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 297 | 0.150 |
Why?
|
| Life Expectancy | 1 | 2018 | 16 | 0.150 |
Why?
|
| Heart Rate | 1 | 2020 | 334 | 0.150 |
Why?
|
| African Americans | 4 | 2013 | 1427 | 0.150 |
Why?
|
| Nutritional Status | 1 | 2018 | 75 | 0.150 |
Why?
|
| Polymorphism, Genetic | 2 | 2013 | 184 | 0.150 |
Why?
|
| Child | 6 | 2020 | 2433 | 0.150 |
Why?
|
| Dyslipidemias | 1 | 2018 | 53 | 0.150 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.150 |
Why?
|
| Oxidative Stress | 1 | 2019 | 230 | 0.150 |
Why?
|
| Leukoencephalopathies | 1 | 2017 | 12 | 0.150 |
Why?
|
| Prognosis | 4 | 2020 | 1505 | 0.150 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 104 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 1062 | 0.150 |
Why?
|
| Hippocampus | 2 | 2020 | 171 | 0.140 |
Why?
|
| Aspirin | 1 | 2017 | 64 | 0.140 |
Why?
|
| Ear, Inner | 2 | 2009 | 9 | 0.140 |
Why?
|
| Coronary Stenosis | 2 | 2008 | 30 | 0.140 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 878 | 0.140 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2018 | 120 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 217 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 56 | 0.140 |
Why?
|
| Progesterone Congeners | 3 | 2006 | 15 | 0.140 |
Why?
|
| Linoleoyl-CoA Desaturase | 1 | 2016 | 1 | 0.140 |
Why?
|
| Diet, Sodium-Restricted | 3 | 2013 | 18 | 0.140 |
Why?
|
| Cytokines | 2 | 2019 | 255 | 0.140 |
Why?
|
| Directive Counseling | 1 | 2016 | 18 | 0.140 |
Why?
|
| Interviews as Topic | 1 | 2017 | 263 | 0.140 |
Why?
|
| Gait | 1 | 2017 | 141 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2017 | 247 | 0.140 |
Why?
|
| Neoplasms | 2 | 2020 | 692 | 0.140 |
Why?
|
| Gyrus Cinguli | 1 | 2016 | 22 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 53 | 0.130 |
Why?
|
| Linoleic Acid | 1 | 2016 | 16 | 0.130 |
Why?
|
| African Continental Ancestry Group | 4 | 2009 | 363 | 0.130 |
Why?
|
| Patient Preference | 1 | 2016 | 47 | 0.130 |
Why?
|
| Self Care | 2 | 2015 | 144 | 0.130 |
Why?
|
| Fatty Acid Desaturases | 1 | 2016 | 48 | 0.130 |
Why?
|
| Prefrontal Cortex | 1 | 2016 | 70 | 0.130 |
Why?
|
| Coronary Vessels | 2 | 2008 | 160 | 0.130 |
Why?
|
| Carotid Arteries | 2 | 2008 | 99 | 0.130 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2015 | 7 | 0.130 |
Why?
|
| Algorithms | 4 | 2014 | 496 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 125 | 0.130 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 106 | 0.130 |
Why?
|
| Troponin T | 1 | 2016 | 81 | 0.130 |
Why?
|
| Incretins | 1 | 2015 | 1 | 0.130 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2015 | 3 | 0.130 |
Why?
|
| Nerve Net | 1 | 2016 | 123 | 0.130 |
Why?
|
| Patient Dropouts | 1 | 2015 | 28 | 0.130 |
Why?
|
| Sensitivity and Specificity | 4 | 2012 | 594 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2015 | 54 | 0.120 |
Why?
|
| Multivariate Analysis | 6 | 2014 | 687 | 0.120 |
Why?
|
| Motor Skills Disorders | 1 | 2014 | 7 | 0.120 |
Why?
|
| Pregnancy Complications | 2 | 2007 | 105 | 0.120 |
Why?
|
| Sleep | 1 | 2015 | 92 | 0.120 |
Why?
|
| Glucose | 1 | 2015 | 174 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 564 | 0.120 |
Why?
|
| Apolipoproteins E | 2 | 2019 | 94 | 0.110 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 23 | 0.110 |
Why?
|
| Carotid Stenosis | 1 | 2014 | 58 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 882 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2013 | 474 | 0.110 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2013 | 14 | 0.110 |
Why?
|
| Electrocardiography | 1 | 2018 | 632 | 0.110 |
Why?
|
| Women's Health Services | 1 | 2013 | 11 | 0.110 |
Why?
|
| Research Subjects | 1 | 2013 | 17 | 0.110 |
Why?
|
| Glucocorticoids | 2 | 2005 | 147 | 0.110 |
Why?
|
| Animals | 5 | 2020 | 7459 | 0.110 |
Why?
|
| Drug Combinations | 2 | 2010 | 95 | 0.110 |
Why?
|
| Sodium, Dietary | 1 | 2013 | 23 | 0.110 |
Why?
|
| Diabetes, Gestational | 1 | 2013 | 24 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2013 | 103 | 0.110 |
Why?
|
| Lower Extremity | 1 | 2013 | 100 | 0.110 |
Why?
|
| Fatty Liver | 1 | 2013 | 65 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2011 | 227 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2012 | 33 | 0.100 |
Why?
|
| Climacteric | 1 | 2012 | 6 | 0.100 |
Why?
|
| Educational Status | 1 | 2013 | 179 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2012 | 57 | 0.100 |
Why?
|
| Counseling | 3 | 2020 | 97 | 0.100 |
Why?
|
| Prednisone | 3 | 2009 | 61 | 0.100 |
Why?
|
| Demography | 2 | 2015 | 109 | 0.100 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2011 | 66 | 0.100 |
Why?
|
| Dysthymic Disorder | 1 | 2011 | 2 | 0.100 |
Why?
|
| Proxy | 1 | 2011 | 9 | 0.100 |
Why?
|
| Dementia, Vascular | 1 | 2011 | 12 | 0.100 |
Why?
|
| Mental Health | 1 | 2012 | 115 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 143 | 0.100 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2011 | 12 | 0.100 |
Why?
|
| Coronary Disease | 2 | 2009 | 213 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 628 | 0.090 |
Why?
|
| Depressive Disorder, Major | 1 | 2011 | 42 | 0.090 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2010 | 3 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2011 | 161 | 0.090 |
Why?
|
| Learning | 1 | 2011 | 79 | 0.090 |
Why?
|
| Liver | 1 | 2013 | 482 | 0.090 |
Why?
|
| Software | 2 | 2014 | 127 | 0.090 |
Why?
|
| Cardiovascular System | 1 | 2010 | 42 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 131 | 0.080 |
Why?
|
| Community Health Services | 1 | 2009 | 56 | 0.080 |
Why?
|
| Pericardium | 1 | 2009 | 52 | 0.080 |
Why?
|
| Coronary Artery Disease | 2 | 2003 | 401 | 0.080 |
Why?
|
| Physical Endurance | 1 | 2009 | 35 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 45 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 286 | 0.080 |
Why?
|
| Rest | 1 | 2008 | 54 | 0.080 |
Why?
|
| Atherosclerosis | 3 | 2013 | 767 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 36 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2011 | 398 | 0.080 |
Why?
|
| Ankle Joint | 1 | 2008 | 35 | 0.080 |
Why?
|
| Gastroplasty | 1 | 2008 | 11 | 0.080 |
Why?
|
| Health Priorities | 1 | 2008 | 15 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 122 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2019 | 97 | 0.080 |
Why?
|
| Video Recording | 2 | 2018 | 59 | 0.080 |
Why?
|
| Statistics as Topic | 2 | 2008 | 108 | 0.080 |
Why?
|
| Cholesterol, LDL | 2 | 2016 | 173 | 0.070 |
Why?
|
| Triglycerides | 2 | 2016 | 230 | 0.070 |
Why?
|
| Sodium Fluoride | 1 | 2007 | 1 | 0.070 |
Why?
|
| Calcium | 2 | 2008 | 307 | 0.070 |
Why?
|
| Prenatal Care | 2 | 2007 | 51 | 0.070 |
Why?
|
| Dental Caries | 1 | 2007 | 22 | 0.070 |
Why?
|
| Xerostomia | 1 | 2007 | 30 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2016 | 894 | 0.070 |
Why?
|
| North Carolina | 4 | 2019 | 1516 | 0.070 |
Why?
|
| Audiometry, Speech | 1 | 2005 | 2 | 0.070 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2005 | 8 | 0.070 |
Why?
|
| Labyrinth Diseases | 1 | 2005 | 7 | 0.070 |
Why?
|
| Heart Failure | 1 | 2011 | 636 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 186 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2011 | 294 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 324 | 0.060 |
Why?
|
| Electronic Mail | 2 | 2014 | 18 | 0.060 |
Why?
|
| Ear Diseases | 1 | 2003 | 7 | 0.060 |
Why?
|
| Radiography | 2 | 2016 | 376 | 0.060 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2003 | 22 | 0.060 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2003 | 10 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2005 | 410 | 0.060 |
Why?
|
| Colonic Polyps | 1 | 2003 | 15 | 0.060 |
Why?
|
| Phenotype | 2 | 2018 | 631 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2003 | 53 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2003 | 45 | 0.060 |
Why?
|
| Methotrexate | 1 | 2003 | 64 | 0.050 |
Why?
|
| Water-Electrolyte Balance | 1 | 2002 | 16 | 0.050 |
Why?
|
| Contrast Media | 1 | 2003 | 138 | 0.050 |
Why?
|
| Mental Recall | 1 | 2002 | 51 | 0.050 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2002 | 11 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2002 | 11 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 240 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2002 | 132 | 0.050 |
Why?
|
| Smoking | 4 | 2009 | 496 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2011 | 18 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2011 | 44 | 0.050 |
Why?
|
| Nitrogen Dioxide | 1 | 2020 | 1 | 0.050 |
Why?
|
| Medicare Part A | 1 | 2020 | 5 | 0.050 |
Why?
|
| Quality Control | 1 | 2021 | 44 | 0.050 |
Why?
|
| Medicare Part B | 1 | 2020 | 5 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 28 | 0.050 |
Why?
|
| Pregnancy | 3 | 2013 | 994 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 216 | 0.050 |
Why?
|
| Ultrasonography | 4 | 2005 | 379 | 0.050 |
Why?
|
| Medicare Part D | 1 | 2020 | 8 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2020 | 18 | 0.050 |
Why?
|
| Bone Density | 1 | 2002 | 203 | 0.050 |
Why?
|
| Morbidity | 1 | 2020 | 99 | 0.040 |
Why?
|
| Ovariectomy | 2 | 2013 | 149 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 57 | 0.040 |
Why?
|
| Running | 1 | 2020 | 19 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2020 | 66 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 37 | 0.040 |
Why?
|
| Psychometrics | 2 | 2012 | 136 | 0.040 |
Why?
|
| Tunica Media | 3 | 2005 | 28 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 4 | 0.040 |
Why?
|
| Optic Disk | 1 | 2019 | 11 | 0.040 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2019 | 14 | 0.040 |
Why?
|
| Rhode Island | 1 | 2019 | 5 | 0.040 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Fast Foods | 1 | 2019 | 4 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 488 | 0.040 |
Why?
|
| Intraocular Pressure | 1 | 2019 | 40 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 35 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2019 | 37 | 0.040 |
Why?
|
| Cues | 1 | 2019 | 68 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 73 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 104 | 0.040 |
Why?
|
| Equipment Design | 1 | 2018 | 172 | 0.040 |
Why?
|
| Energy Intake | 1 | 2019 | 128 | 0.040 |
Why?
|
| Continental Population Groups | 2 | 2009 | 237 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 55 | 0.040 |
Why?
|
| Rotation | 1 | 2017 | 47 | 0.040 |
Why?
|
| Hospitalization | 1 | 2020 | 469 | 0.040 |
Why?
|
| Losartan | 1 | 2017 | 64 | 0.040 |
Why?
|
| Placebos | 2 | 2009 | 63 | 0.040 |
Why?
|
| Adolescent Health Services | 1 | 2017 | 12 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 473 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2016 | 15 | 0.030 |
Why?
|
| Postal Service | 1 | 2016 | 7 | 0.030 |
Why?
|
| Ethnic Groups | 2 | 2009 | 476 | 0.030 |
Why?
|
| Muscle Stretching Exercises | 1 | 2015 | 6 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 56 | 0.030 |
Why?
|
| Schools | 1 | 2016 | 67 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 547 | 0.030 |
Why?
|
| Forecasting | 1 | 2006 | 144 | 0.030 |
Why?
|
| Sample Size | 1 | 2015 | 38 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 160 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2015 | 57 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 98 | 0.030 |
Why?
|
| Resistance Training | 1 | 2015 | 82 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2014 | 76 | 0.030 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2013 | 57 | 0.030 |
Why?
|
| Computational Biology | 1 | 2014 | 91 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 125 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 109 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2014 | 66 | 0.030 |
Why?
|
| Macaca | 1 | 2013 | 24 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 30 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 113 | 0.030 |
Why?
|
| Diet, Atherogenic | 1 | 2013 | 61 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2013 | 42 | 0.030 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2013 | 13 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2014 | 173 | 0.030 |
Why?
|
| Atrophy | 1 | 2013 | 46 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2013 | 163 | 0.030 |
Why?
|
| RNA | 1 | 2013 | 91 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2013 | 90 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2013 | 125 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 124 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2012 | 57 | 0.030 |
Why?
|
| Gene Expression | 1 | 2013 | 333 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 28 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 191 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 268 | 0.020 |
Why?
|
| Intention | 1 | 2011 | 28 | 0.020 |
Why?
|
| Hand Strength | 1 | 2011 | 101 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2011 | 10 | 0.020 |
Why?
|
| Horses | 1 | 2011 | 13 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 24 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2011 | 36 | 0.020 |
Why?
|
| Thinness | 1 | 2011 | 32 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2012 | 165 | 0.020 |
Why?
|
| Space Perception | 1 | 2009 | 27 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 485 | 0.020 |
Why?
|
| Diabetic Neuropathies | 1 | 2009 | 24 | 0.020 |
Why?
|
| Prediabetic State | 1 | 2009 | 65 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2009 | 85 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 58 | 0.020 |
Why?
|
| Diabetic Retinopathy | 1 | 2009 | 65 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 158 | 0.020 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2009 | 65 | 0.020 |
Why?
|
| Research | 1 | 2009 | 74 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 292 | 0.020 |
Why?
|
| Albuminuria | 1 | 2009 | 181 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2008 | 49 | 0.020 |
Why?
|
| Streptococcus mutans | 1 | 2007 | 4 | 0.020 |
Why?
|
| Tablets | 1 | 2007 | 11 | 0.020 |
Why?
|
| Informed Consent | 1 | 2007 | 34 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2007 | 34 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 2007 | 22 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2007 | 18 | 0.020 |
Why?
|
| Vitamin D | 1 | 2008 | 183 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2007 | 82 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2007 | 140 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2005 | 3 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 407 | 0.020 |
Why?
|
| Speech Perception | 1 | 2005 | 5 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 765 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 194 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 207 | 0.020 |
Why?
|
| Death Certificates | 1 | 2004 | 5 | 0.010 |
Why?
|
| Medical Record Linkage | 1 | 2004 | 4 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 918 | 0.010 |
Why?
|
| Vasodilation | 1 | 2004 | 93 | 0.010 |
Why?
|
| Audiometry | 1 | 2003 | 4 | 0.010 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2003 | 2 | 0.010 |
Why?
|
| Texas | 1 | 2003 | 36 | 0.010 |
Why?
|
| Colorado | 1 | 2003 | 41 | 0.010 |
Why?
|
| California | 1 | 2003 | 62 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2003 | 73 | 0.010 |
Why?
|
| Anthropometry | 1 | 2003 | 83 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 182 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 61 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2003 | 112 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2002 | 152 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 2472 | 0.010 |
Why?
|
| Mutation | 1 | 2002 | 488 | 0.010 |
Why?
|
| Hispanic Americans | 1 | 2003 | 941 | 0.010 |
Why?
|